期刊文献+

探讨生长抑素联合血必净治疗急性重症胰腺炎临床疗效及安全性 预览

Discussion on the clinical efficacy and safety of somatostatin combined with Xuebijing in the treatment of severe acute pancreatitis
在线阅读 免费下载
分享 导出
摘要 目的 探究生长抑素联合血必净治疗急性重症胰腺炎的临床疗效及安全性。方法 24例急性重症胰腺炎患者,随机分为实验组和对照组,各12例。对照组给予单纯生长抑素治疗,实验组在对照组基础上联合血必净治疗,比较两组患者临床症状恢复时间、肿瘤坏死因子-α、超敏C反应蛋白、白介素-8水平及实验组治疗前后血压、心率水平,并观察患者有无不良反应发生。结果 实验组患者肠道功能恢复时间、腹痛腹胀恢复时间分别为(2.58±1.06)、(1.73±0.82)d,均短于对照组的(4.85±1.54)、(3.99±1.22)d,差异具有统计学意义(P<0.05)。实验组肿瘤坏死因子-α、超敏C反应蛋白、白介素-8水平均低于对照组,差异具有统计学意义(P<0.05)。实验组患者治疗前平均收缩压为(108.53±6.02)mm Hg(1 mm Hg=0.133 kPa),治疗后平均收缩压为(110.86±5.17)mm Hg,比较差异无统计学意义(P>0.05);治疗前平均舒张压为(79.66±5.84)mm Hg,治疗后平均舒张压为(80.72±5.56)mm Hg,比较差异无统计学意义(P>0.05);治疗前平均心率为(74.94±4.13)次/min,治疗后平均心率为(78.22±5.67)次/min,比较差异无统计学意义(P>0.05)。且患者无其他明显不良反应发生。结论 生长抑素联合血必净治疗急性重症胰腺炎可加快临床症状改善,降低体内炎症因子水平,安全性良好,具有重要临床意义值得推广。 Objective To investigate the clinical efficacy and safety of somatostatin combined with Xuebijing in the treatment of severe acute pancreatitis. Methods A total of 24 severe acute pancreatitis patients were randomly divided into experimental group and control group, with 12 cases in each group. The control group was treated with simple somatostatin, and the experimental group was treated with Xuebijing on the basis of the control group. The recovery time of clinical symptoms, levels of tumor necrosis factor-α, high-sensitivity C-reactive protein, interleukin-8, blood pressure and heart rate before and after treatment were compared between the two groups, and blood pressure and heart rate before and after treatment and occurrence of adverse reactions in the experimental group, Results The experimental group had shorter recovery time of intestinal function, abdominal pain and abdominal distention respectively as(2.58±1.06) and(1.73±0.82) d than(4.85±1.54) and(3.99±1.22) d in the control group, and their difference was statistically significant(P<0.05). The experimental group had lower tumor necrosis factor-α, high-sensitivity C-reactive protein, interleukin-8 levels than the control group, and the difference was statistically significant(P<0.05). The experimental group had systolic blood pressure before treatment as(108.53±6.02) mm Hg(1 mm Hg=0.133 kPa), which was(110.86±5.17) mm Hg after treatment, and the difference was statistically significant(P>0.05). The mean diastolic blood pressure before treatment was(79.66±5.84) mm Hg, and the mean diastolic blood pressure after treatment was(80.72± 5.56) mm Hg. The difference was not statistically significant(P>0.05). The average heart rate before treatment was(74.94±4.13). times/min, and the average heart rate after treatment was(78.22±5.67) times/min. The difference was not statistically significant(P>0.05). There was no other obvious adverse reactions occurred. Conclusion Combination of somatostatin and Xuebijing in treating severe acute pancreatitis can s
作者 欧光武 梁日光 黄燕金 梁永任 潘保全 OU Guang-wu;LIANG Ri-guang;HUANG Yan-jin(Guangdong Gaozhou People’s Hospital,Gaozhou 525200,China)
出处 《中国现代药物应用》 2019年第1期11-13,共3页 Chinese Journal of Modern Drug Application
关键词 急性重症胰腺炎 生长抑素 血必净 安全性评价 随机对照试验 Severe acute pancreatitis Somatostatin Xuebijing Safety evaluation Randomized controlled trial
  • 相关文献

参考文献7

二级参考文献63

共引文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈